Correction to: Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells (Nature Immunology, (2017), 18, 9, (1004-1015), 10.1038/ni.3800);Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells

Nature Immunology

Volumn 18, Issue 9, 2017, Pages 1004-1015

  Gao, Yulong ^a,b   Souza Fonseca Guimaraes, Fernando ^a,c,d   Bald, Tobias ^a   Ng, Susanna S ^a,e   Young, Arabella ^a,b   Ngiow, Shin Foong ^a   Rautela, Jai ^c   Straube, Jasmin ^a   Waddell, Nic ^a   Blake, Stephen J ^a   Yan, Juming ^a,b   Bartholin, Laurent ^f   Lee, Jason S ^a   Vivier, Eric ^g   Takeda, Kazuyoshi ^h   Messaoudene, Meriem ⁱ   Zitvogel, Laurence ^i,j   Teng, Michele W L ^a,b   Belz, Gabrielle T ^c   Engwerda, Christian R ^a   Huntington, Nicholas D ^c   Nakamura, Kyohei ^a   Hölzel, Michael ^k   Smyth, Mark J ^a,b   more..

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f UNIVERSITÉ LYON 1   (France)

^g CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^h JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNIVERSITÉ PARIS SACLAY   (France)

^k UNIVERSITY OF BONN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTEGRIN; ALPHA2 INTEGRIN; CHEMOKINE RECEPTOR CXCR6; GAMMA INTERFERON; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PLASTICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EXPERIMENTAL LUNG METASTASIS; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOID CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CASE CONTROL STUDY; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FIBROSARCOMA; FLOW CYTOMETRY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE EXPRESSION PROFILING; HUMAN; IMMUNOLOGY; LYMPHOCYTE; NUCLEAR REPROGRAMMING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSARCOMA; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LYMPHOCYTES; MICE; NEOPLASMS, EXPERIMENTAL; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 85027867260     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/s41590-024-01799-9     Document Type: Erratum

References (65)

1. Guillerey, C., Huntington, N.D., Smyth, M.J. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025-1036 (2016).
2. Yang, L., Pang, Y., Moses, H.L. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31, 220-227 (2010).
3. Wrzesinski, S.H., Wan, Y.Y., Flavell, R.A. Transforming growth factor-and the immune response: Implications for anticancer therapy. Clin. Cancer Res. 13, 5262-5270 (2007).
4. Smyth, M.J., Strobl, S.L., Young, H.A., Ortaldo, J.R., Ochoa, A.C. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J. Immunol. 146, 3289-3297 (1991).
5. Donatelli, S.S., et al. TGF-inducible microRNA-183 silences tumor-associated natural killer cells. Proc. Natl. Acad. Sci. USA 111, 4203-4208 (2014).
6. Wilson, E.B., et al. Human tumour immune evasion via TGF-blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 6, e22842 (2011).
7. Smyth, M.J., et al. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176, 1582-1587 (2006).
8. Viel, S., et al. TGF-inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, 19 (2016).
9. Sojka, D.K., et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. eLife 3, e01659 (2014).
10. Constantinides, M.G., McDonald, B.D., Verhoef, P.A., Bendelac, A. A committed precursor to innate lymphoid cells. Nature 508, 397-401 (2014).
11. Fuchs, A. ILC1s in tissue inflammation and infection. Front. Immunol. 7, 104 (2016).
12. Robinette, M.L., et al. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16, 306-317 (2015).
13. Seillet, C., et al. Differential requirement for Nfil3 during NK cell development. J. Immunol. 192, 2667-2676 (2014).
14. Gasteiger, G., Fan, X., Dikiy, S., Lee, S.Y., Rudensky, A.Y. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350, 981-985 (2015).
15. Klose, C.S., et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 157, 340-356 (2014).
16. Spits, H., Bernink, J.H., Lanier, L. NK cells and type 1 innate lymphoid cells: Partners in host defense. Nat. Immunol. 17, 758-764 (2016).
17. Seillet, C., Belz, G.T. Differentiation and diversity of subsets in group 1 innate lymphoid cells. Int. Immunol. 28, 3-11 (2016).
18. Vallentin, B., et al. Innate Lymphoid Cells in Cancer. Cancer Immunol. Res. 3, 1109-1114 (2015).
19. Morvan, M.G., Lanier, L.L. NK cells and cancer: You can teach innate cells new tricks. Nat. Rev. Cancer 16, 7-19 (2016).
20. Cortez, V.S., et al. Transforming growth factor-signaling guides the differentiation of innate lymphoid cells in salivary glands. Immunity 44, 1127-1139 (2016).
21. Keskin, D.B., et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16 NK cells with similarities to decidual NK cells. Proc. Natl. Acad. Sci. USA 104, 3378-3383 (2007).
22. Narni-Mancinelli, E., et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc. Natl. Acad. Sci. USA 108, 18324-18329 (2011).
23. Ruijtenberg, S., van den Heuvel, S. Coordinating cell proliferation and differentiation: Antagonism between cell cycle regulators and cell type-specific gene expression. Cell Cycle 15, 196-212 (2016).
24. Liberzon, A., et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417-425 (2015).
25. Smyth, M.J., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191, 661-668 (2000).
26. Smyth, M.J., Crowe, N.Y., Godfrey, D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459-463 (2001).
27. Sathe, P., et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun. 5, 4539 (2014).
28. Knight, D.A., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123, 1371-1381 (2013).
29. Krasnova, Y., Putz, E.M., Smyth, M.J., Souza-Fonseca-Guimaraes, F. Bench to bedside: NK cells and control of metastasis. Clin. Immunol. 177, 50-59 (2017).
30. Chaput, N., et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLADR+ NK cell levels correlate with disease outcome. OncoImmunology 2, e23080 (2013).
31. Ménard, C., et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 69, 3563-3569 (2009).
32. Fuchs, A., et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-producing cells. Immunity 38, 769-781 (2013).
33. Crome, S.Q., et al. A distinct innate lymphoid cell population regulates tumorassociated T cells. Nat. Med. 23, 368-375 (2017).
34. Dadi, S., et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365-377 (2016).
35. Pikovskaya, O., et al. Cutting edge: Eomesodermin is sufficient to direct type 1 innate lymphocyte development into the conventional NK lineage. J. Immunol. 196, 1449-1454 (2016).
36. Cortez, V.S., et al. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-signaling. Nat. Immunol. doi:10.1038/ni.3809 (2016).
37. Hayakawa, Y., et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand,-galactosylceramide. Blood 100, 1728-1733 (2002).
38. Ikeda, H., Old, L.J., Schreiber, R.D. The roles of IFNin protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13, 95-109 (2002).
39. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361-371 (2009).
40. Baluk, P., et al. TNF-drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J. Clin. Invest. 119, 2954-2964 (2009).
41. Sainson, R.C., et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111, 4997-5007 (2008).
42. Gill, S., et al. Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119, 5758-5768 (2012).
43. Doisne, J.M., et al. Composition, development, and function of uterine innate lymphoid cells. J. Immunol. 195, 3937-3945 (2015).
44. Levi, I., et al. Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6, 13835-13843 (2015).
45. Bruno, A., et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15, 133-142 (2013).
46. Lima, P.D., Zhang, J., Dunk, C., Lye, S.J., Croy, B.A. Leukocyte drivendecidual angiogenesis in early pregnancy. Cell. Mol. Immunol. 11, 522-537 (2014).
47. Vacca, P., et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc. Natl. Acad. Sci. USA 107, 11918-11923 (2010).
48. Arteaga, C.L., et al. Anti-transforming growth factor (TGF)-antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-interactions in human breast cancer progression. J. Clin. Invest. 92, 2569-2576 (1993).
49. Terabe, M., et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-monoclonal antibody. Clin. Cancer Res. 15, 6560-6569 (2009).
50. Morris, J.C., et al. Phase I study of GC1008 (fresolimumab): A human antitransforming growth factor-(TGF) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 9, e90353 (2014).
51. Akhurst, R.J., Hata, A. Targeting the TGFsignalling pathway in disease. Nat. Rev. Drug Discov. 11, 790-811 (2012).
52. Viant, C., et al. Transforming growth factor-and Notch ligands act as opposing environmental cues in regulating the plasticity of type 3 innate lymphoid cells. Sci. Signal. 9, 46 (2016).
53. Kara, E.E., et al. CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells. Nat. Commun. 6, 8644 (2015).
54. Johnstone, C.N., et al. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis. Model. Mech. 8, 237-251 (2015).
55. Blake, S.J., et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6, 446-459 (2016).
56. Souza-Fonseca-Guimaraes, F., et al. NK cells require IL-28R for optimal in vivo activity. Proc. Natl. Acad. Sci. USA 112, E2376-E2384 (2015).
57. Delconte, R.B., et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17, 816-824 (2016).
58. Rautela, J., et al. Loss of Host Type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer. Cancer Immunol. Res. 3, 1207-1217 (2015).
59. Ngiow, S.F., et al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res. 75, 3800-3811 (2015).
60. Liao, Y., Smyth, G.K., Shi, W. The Subread aligner: Fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
61. Law, C.W., Chen, Y., Shi, W., Smyth, G.K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
62. Ritchie, M.E., et al. limma powers differential expression analyses for RNAsequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
63. Subramanian, A., et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
64. Lee, E., Chuang, H.Y., Kim, J.W., Ideker, T., Lee, D. Inferring pathway activity toward precise disease classification. PLOS Comput. Biol. 4, e1000217 (2008).
65. Bald, T., et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 507, 109-113 (2014).